Despite last year’s sharp decline in approvals, registrations of two RNA drugs offer a window into the current state and possible future of drug development. Looking forward, the sector seeks greater clarity on the new presidential administration’s priorities and the impact of new healthcare legislation. Chris Morrison reports.
NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 2 FEBRUARY 2017
Para acessar a publicação na íntegra clique aqui